Global Immune Checkpoint Inhibitors Market Reaches USD 2,369.6 Mn in 2026, Driven by Rising Cancer Incidence and Growing Adoption of Immunotherapy

Clinical Advancements and Expanding Oncology Indications to Drive Global Immune Checkpoint Inhibitors Market to USD 5,615.6 Mn by 2033 at 13.2% CAGR – Coherent Market Insights

Global Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,369.6 Million in 2026 and is expected to exhibit a CAGR of 13.2% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Major manufacturers are investing into R&D to develop immune-checkpoint therapies by understanding tumor functions and ways to combat them. Manufacturers are focusing on upgrading available immune checkpoint inhibitors as well as developing new immune checkpoint inhibitors for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In March 2017, Avelumab (Bavencio), jointly developed by EMD Serono, and Pfizer, Inc. received U.S. Food & Drug Administration (FDA) approval for the treatment of metastatic merkel cell carcinoma. In 2017, the U.S. FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC).

Global Immune Checkpoint Inhibitors Market: Key Developments

• In February 2026, Exelixis, Inc., a genomics-based drug discovery company announced that the U.S. FDA accepted its New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer. The application is supported by Phase 3 STELLAR-303 data showing improved median overall survival and reduced risk of death versus regorafenib. FDA assigned a standard review, with a Prescription Drug User Fee Act target action date of December 3, 2026, marking important progress for Exelixis’ oncology pipeline. (Source: Exelixis, Inc.)
• In May 2026, OncLive reported that muscle-invasive bladder cancer treatment is shifting from cisplatin-based chemotherapy toward immune checkpoint inhibitors, antibody-drug conjugates, and biomarker-guided strategies. Experts highlighted adjuvant nivolumab from CheckMate 274, perioperative durvalumab in NIAGARA, and enfortumab vedotin plus pembrolizumab trials as key advances. ctDNA testing is also gaining clinical utility by identifying patients who may benefit from adjuvant immune checkpoint blockade after surgery, supporting a more personalized treatment approach in bladder cancer.
• In March 2026, INOVIO and Akeso announced a clinical collaboration to evaluate INOVIO’s INO-5412 DNA immunotherapy with Akeso’s cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, for glioblastoma. The combination will be assessed in the Dana-Farber-sponsored Phase 2 INSIGhT adaptive platform trial, with dosing expected to begin in the second half of 2026. The study highlights growing interest in dual checkpoint inhibition and combination immunotherapy for aggressive brain cancers with high unmet clinical need worldwide.

Browse 46 Market Data Tables and 41 Figures spread through 238 Pages and in-depth TOC on “Global Immune Checkpoint Inhibitors Market”-  Forecast to 2033, Global Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/immune-checkpoint-inhibitors-market-2560

Moreover, increasing approval by the regulatory bodies is expected to drive the market growth over the forecast period. For instance, in January 2018, the U.S. Food & Drug Administration (FDA) granted breakthrough therapy status to Lenvima-Keytruda combo for advanced kidney cancer. Furthermore, in February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. Moreover, Genentech combination therapy Tecentriq and Avastin delayed kidney cancer progression in Phase III trials in December 2017. AstraZeneca Plc’s Imfinzi (Durvalumab) showed delayed non-small cell lung cancer progression in Phase III trials in November 2017.

Key Takeaways of the Global Immune Checkpoint Inhibitors Market

• The global immune checkpoint inhibitors market is expected to exhibit a CAGR of 13.2% during the forecast period due to the increasing adoption of inorganic strategies such as collaborations by the key players in the market for developing immune checkpoint inhibitors. For instance, in June 2020, Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors collaborated with the Explorations in Global Health (ExGloH) Division of Leidos to evaluate the potential of using ONCOS oncolytic adenoviruses as a vector to encode Microtide checkpoint inhibitor peptides. Targovax’s clinical program is focused on combining ONCOS viruses with checkpoint inhibitors. This combination is promising since checkpoint inhibition complements oncolytic virotherapy by blocking the tumor’s main defense mechanism against the anti-tumor immune response generated by the oncolytic virus.
• Biopharmaceutical companies are developing a robust pipeline of immune-checkpoint inhibitor combination therapies due to their increasing demand. The U.S. Food & Drug Administration (FDA) has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1). Furthermore, in April 2021, Kuwait Cancer Control Center, Company that provides Cancer Care, carried out research study on Drug: Pembrolizumab used as Immune Check Point Inhibitor. The study is in the phase 2 Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer. The primary completion date of study is estimated to be September 30, 2022.
• The hospital pharmacies segment is estimated to hold a dominant position in the global immune checkpoint inhibitors market over the forecast period, owing to the increased prevalence of cancer and introduction of new innovative novel treatment therapy. For instance, in May 2021, according to the data published by the American Society of Clinical Oncology and Association for Clinical Oncology phase III studies evaluating combinations of immune checkpoint inhibitors had only demonstrated clinical benefit by blocking the PD-1 and CTLA-4 pathways. Nivolumab acts on the PD-1 protein and is FDA-approved for the treatment of patients with melanoma and several other cancer types. Relatlimab is the first to bind to LAG-3 on T cells, reinvigorating their activity and potentially unleashing enhanced anti-tumor responses. The researchers found that the median PFS was significantly longer with nivolumab and relatlimab compared with nivolumab alone, 10.1 versus 4.6 months, respectively. At 1 year, PFS rates were 47.7% for patients receiving the immunotherapy combination and 36.0% for those receiving nivolumab alone. TRAEs associated with nivolumab and relatlimab were generally manageable and reflected the typical safety profile seen with immune checkpoint inhibitors. Furthermore, according to data published by the U.S. Department of Health and Human Services, as of January 2022, it is estimated that there are 18.1 million cancer survivors in the United States. This represents approximately 5.4% of the population. The number of cancer survivors is projected to increase by 24.4%, to 22.5 million, by 2032. The number of cancer survivors is projected to grow to 26.0 million by 2040. Over the next decade, the number of people who have lived 5 or more years after their cancer diagnosis is projected to increase approximately 30%, to 16.3 million.
• Major players operating in the global immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.